Current Partnerships

  • ONK Therapeutics is open to a range of partnering and collaborative approaches to advance its technologies and products
  • ONK Therapeutics currently has several collaborations with a number of key players in the cell therapy space including:
    • National Institutes of Health, Bethesda, MD, USA: working on the utilization of TRAIL variant to enhance autologous NK cell therapy. ONK Therapeutics has a CRADA with the NIH
    • VU University Medical Center (VUMC), Amsterdam, Netherlands: working on the optimization of CD38 CAR-NK cells
    • Xi’an Jiatong University, Shaanxi, China: working on cancer microenvironmental factors

Future Partnerships

ONK Therapeutics is interested in forming partnership and collaborations in the following areas:

  • Partnerships and collaboration with biopharmaceutical companies to develop and commercialize optimized NK cell therapies
  • Out-Licensing of ONK Therapeutics technologies to enhance partner NK cell therapy approaches
  • In-Licensing of technologies to enhance the ONK Therapeutics platform
  • Potential combined therapeutic approaches utilizing the ONK Therapeutics cell therapy products with other anti-cancer therapies

If you are interested in partnering with ONK Therapeutics, please go the contact page.